Written by Dr. Archana Agarwal — Endometriosis Specialist in Bangalore, Founder & Medical Director, Mannat Fertility Clinic

Endometriosis care is living through one of its most active research stretches in decades. For a condition that took an age to be taken seriously in the first place - and that still, globally, carries a seven to ten year delay before anyone gets a diagnosis - the current pipeline of treatments, and the quality of the evidence sitting behind them, amounts to real progress. So here is what the latest research is actually showing, and what it means for women living with endometriosis right now.

Why This Moment Matters for Endometriosis Treatment

For a long time the medical options here were blunt instruments. Hormonal therapies that either shut ovulation down completely - useful for pain, useless if you are trying to conceive - or injectable GnRH agonists that mimicked menopause, and came with heavy side effects, bone density loss and severe vasomotor symptoms among them. 

Surgery was the other route, laparoscopic excision of the lesions, but the recurrence rates ran high and every repeat operation brought its own risks, reduced ovarian reserve among them.

What has shifted lately is the arrival of a new class of oral medications, better evidence on how to sequence treatment for fertility preservation, and a clearer read from the large-scale guidelines on which interventions genuinely move the needle - and, just as usefully, which ones do not.

The New Class: Oral GnRH Antagonists

If you ask me what the single most clinically significant development in endometriosis pharmacology has been these past few years, it is this: the oral GnRH receptor antagonists finally got approved. The older injectable agonists had an awkward habit - they set off an initial hormonal flare before the suppression ever kicked in. The antagonists skip that entirely. Block the receptor directly and estrogen production drops more cleanly, and a good deal faster too. Three agents matter here:

• Elagolix, which already holds approval in several countries

• Relugolix - this one is cleared across the UK and EU for moderate-to-severe endometriosis-associated pain

• And linzagolix. The newest of them. The NHS signed off on it in England in 2025.

A 2025 meta-analysis in the Journal of Clinical Medicine Research weighed up the clinical efficacy and the safety profile of these oral antagonists, and where it landed is worth hearing: a particularly promising approach, set against the older hormonal treatments. 

Dose-dependent pain reduction. A lighter impact on bone mineral density, especially when you pair them with add-back therapy - a low-dose hormone add-back that takes the edge off the menopausal side effects. And I would not underrate the practical part either. Being able to adjust the dose to the treatment goal, and to take the thing at home rather than trekking to a clinic, is genuinely meaningful for patients who have spent years travelling for injections.

Now the honest caveat. These are not yet widely available in India. Their approval trajectory across Europe and the US, though, means they are likely to become more accessible here in the coming years - and if you are planning management over the longer term, that is worth knowing today.

What the ESHRE 2022 Guideline Clarified

For women managing endometriosis alongside a wish to conceive, the most authoritative reference we have right now is the 2022 ESHRE endometriosis guideline. A few of its findings deserve to be heard straight, not second-hand through a clinic's stock recommendations:

• Hormonal suppression is not the way to improve your natural fertility. GnRH agonists included. That is a real correction to how things used to be done - suppress the lesions, the old thinking went, and your conception odds climb afterward. The evidence just does not back it up. The medications are for pain. Spontaneous pregnancy rates do not shift.

• Early-stage disease, meaning rASRM stage I or II, does not call for routine surgery before ART. Why not? Because no live birth benefit turned up in the data, and you can lose ovarian reserve on the operating table.

• Endometriomas are the one place surgery earns a second look. Only if the goal is genuinely better follicle access for an egg retrieval, mind you - and even then it is a careful call, made with your reproductive history and your AMH in front of us.

• And for stage I or II, ESHRE would rather you run IUI with ovarian stimulation than sit and wait it out. The more advanced stages, tubes open? IUI with stimulation stays on the table. The evidence gets thinner the further out you go, though, and I will not pretend otherwise.

Fertility Preservation: A Growing Priority

Here is a first that slipped past most people. The 2022 ESHRE guideline formally treated fertility preservation in women with endometriosis as its own distinct consideration - the first guideline to do so - recognising that the progressive ovarian damage from endometriomas and from repeat surgeries turns this into an active risk-management question. Not merely a plan for the future. A large retrospective study looked at women with endometriomas who went through oocyte vitrification and found cumulative live birth rates of 46.4%, which backs fertility preservation as a clinically valid option for women with significant ovarian endometriosis who are not ready to conceive yet.

So who does this actually apply to? Any woman with bilateral endometriomas, or a history of ovarian surgery, who has not yet completed her family. The window for meaningful egg banking narrows with each surgical episode. And the AMH - I have watched this catch people off guard - can drop faster than you would expect in ovaries affected by endometriosis.

What Hasn't Changed

For all the genuine advances, a few realities hold steady. Endometriosis is still, for many women, a progressive condition. And early diagnosis remains the single most useful intervention we have - not because it unlocks some dramatic treatment, but because it preserves options. Think about what a woman who knows she has endometriosis at 27 can actually do: fertility preservation, staging her family-building timeline, starting fertility-oriented treatment before the reserve is affected. Considerably more room to plan than the woman who finally gets a confirmed diagnosis at 34, after years of being told it was nothing.

Pain symptoms brushed off as "normal periods" are the most common reason for that diagnostic gap. Persistent dysmenorrhea, the painful periods. Dyspareunia, pain during intercourse. Chronic pelvic pain. When these are disrupting daily life, they are worth investigating - not managing with over-the-counter pain relief indefinitely.

When to See an Endometriosis Specialist

Book an evaluation if any of this sounds like you. Your periods are reliably painful enough to interfere with how you function. You have been trying to conceive for six months or more without success. Or a previous scan flagged a pelvic cyst that never got followed up properly. At Mannat Fertility Clinic, Dr Archana treat endometriosis in Bangalore as the intersection of pain management and fertility planning that it really is - because for most women with this condition, those two conversations cannot be fully pulled apart.

This article is for general information only and is not a substitute for individualised medical advice. Treatment decisions for endometriosis should be made with a specialist, based on your stage, your symptoms, your fertility plans, and your ovarian reserve.